Skip to content

#生物标志物

Today 0 items
Oct 8Thu
  1. medicalxpress.com61

    NHS labs fail to share data vital for diagnosis and care of rare diseases, investigation finds

    A BMJ investigation finds that three of England's seven NHS Genomics Laboratory Hubs, those covering South East, South West, and North East and Yorkshire, are not routinely submitting genetic variants to public databases such as ClinVar, as required since 2024 under ACGS guidance. Even hubs that submit face significant backlogs. The labs cite staffing, technology and infrastructure gaps and say they plan routine submissions this year, while experts warn rare disease patients are missing out on diagnosis and care.

    Why it matters: Non-sharing of NHS variant data limits rare disease diagnosis and public value of genomic testing.

Sep 24Thu
  1. STAT News59

    STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks

    An FDA advisory panel endorsed Galleri, Grail's blood test to screen for multiple types of cancer, voting 10 to 0 that there is reasonable assurance the test is safe. The panel split 6 to 4 on effectiveness and voted 7 to 2 with one abstention that benefits outweigh risks for patients meeting the proposed indication's criteria. The FDA is not obliged to follow the panel's advice but often does.

    Why it matters: Advisory panel backing moves a multi-cancer screening blood test closer to potential FDA decision.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org